Literature DB >> 21320235

Predicting weight using postmenstrual age--neonates to adults.

Anita L Sumpter1, Nick H G Holford.   

Abstract

OBJECTIVES: To describe the pattern and variability of body weight with postmenstrual age (PMA) using nonlinear mixed effect modeling and to create a single mathematical function that can be used from prematurity to adulthood.
BACKGROUND: PMA has been shown to predict functional properties of humans such as glomerular filtration rate and drug clearance. Widely used growth charts use postnatal age to predict weight in an idealized population and are not available as a mathematical function.
METHODS: We modeled 7164 body weight and PMA observations from a pooled database of 5031 premature neonates, infants, children, and adults. All subjects were participants in pharmacokinetic or renal function studies. PMA ranged from 23 weeks to 82 years. A mixed effect model was used to describe fixed (PMA, sex) and random between-subject variability.
RESULTS: A model based on the sum of three sigmoid hyperbolic and one exponential functions described the data. Females were typically 12% lighter in weight. Part of the between-subject variability in weight decreased exponentially with a half-life of 3.5 PMA years, while the remainder stayed a constant fraction of the weight asymptote for each of the four functions.
CONCLUSIONS: The change of weight with PMA and sex can be described with a simple equation. This is suitable for simulation of typical weight-age distributions and may be useful for evaluation of appropriate weight for age in children requiring medical treatment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21320235     DOI: 10.1111/j.1460-9592.2011.03534.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  10 in total

1.  Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Authors:  Joseph F Standing; Brian J Anderson; Stefanie Hennig; Nick H Holford; Trevor N Johnston; Catherijne A J Knibbe; Dagan O Lonsdale; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

2.  Predicting pediatric age-matched weight and body mass index.

Authors:  Sherwin K B Sy; Eduardo Asin-Prieto; Hartmut Derendorf; Emil Samara
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

3.  Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible.

Authors:  Salvatore D'Agate; Flora Tshinanu Musuamba; Oscar Della Pasqua
Journal:  Front Pharmacol       Date:  2020-09-25       Impact factor: 5.810

4.  Pharmacokinetic models of morphine and its metabolites in neonates:: Systematic comparisons of models from the literature, and development of a new meta-model.

Authors:  Katrine Rørbæk Knøsgaard; David John Richard Foster; Mads Kreilgaard; Eva Sverrisdóttir; Richard Neil Upton; Johannes N van den Anker
Journal:  Eur J Pharm Sci       Date:  2016-07-01       Impact factor: 4.384

5.  Pharmacokinetics of Penicillin G in Preterm and Term Neonates.

Authors:  Helgi Padari; Tuuli Metsvaht; Eva Germovsek; Charlotte I Barker; Karin Kipper; Koit Herodes; Joseph F Standing; Kersti Oselin; Tõnis Tasa; Hiie Soeorg; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Nonparametric goodness-of-fit testing for parametric covariate models in pharmacometric analyses.

Authors:  Niklas Hartung; Martin Wahl; Abhishake Rastogi; Wilhelm Huisinga
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-04

7.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

8.  Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.

Authors:  Robert Chiesa; Joseph F Standing; Robert Winter; Zohreh Nademi; Jan Chu; Danielle Pinner; Frank Kloprogge; Susan McLellen; Persis J Amrolia; Kanchan Rao; Giovanna Lucchini; Juliana Silva; Oana Ciocarlie; Arina Lazareva; Andrew R Gennery; Bilyana Doncheva; Andrew J Cant; Sophie Hambleton; Terence Flood; Elizabeth Rogerson; Kirsty Devine; Helen Prunty; Simon Heales; Paul Veys; Mary Slatter
Journal:  Clin Pharmacol Ther       Date:  2019-12-14       Impact factor: 6.875

9.  A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

Authors:  Koichiro Yoneyama; Christophe Schmitt; Tiffany Chang; Christophe Dhalluin; Sayaka Nagami; Claire Petry; Gallia G Levy
Journal:  J Clin Pharmacol       Date:  2021-11-08       Impact factor: 2.860

10.  Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.

Authors:  Leonid Gibiansky; Patanjali Ravva; Neil J Parrott; Rajinder Bhardwaj; Elke Zwanziger; Paul Grimsey; Barry Clinch; Stefan Sturm
Journal:  Clin Pharmacol Ther       Date:  2020-02-26       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.